Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Depleted Stem Cell Transplant Clear all
Completed Phase 2 Interventional Results available

HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

NCT01119066
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
Interventions
total body irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine, Clofarabine, (CliniMACS) T-cell depleted PBSC Transplant
Radiation · Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 69 Years
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 4 Interventional

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00003398
View directory record Official record
Conditions
Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, thiotepa, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 5, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional

Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies

NCT07285668
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 5, 2026, 7:23 PM EDT
Suspended Phase 2 Interventional

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

NCT05617625
View directory record Official record
Conditions
Myelodysplastic Syndromes, Graft Vs Host Disease, Graft-versus-host-disease
Interventions
Busulfan, Melphalan, Fludarabine, CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)
Drug · Device
Lead sponsor
Guenther Koehne
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders

NCT00587054
View directory record Official record
Conditions
Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 5, 2026, 7:23 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia

NCT03431090
View directory record Official record
Conditions
Myelodysplasia, Hematologic Malignancy
Interventions
CliniMACS® TCRαβ/CD19 Combined Depletion System
Device
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 30 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Not applicable Interventional

CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

NCT00333190
View directory record Official record
Conditions
Hematologic Malignancy, AML, ALL, CML, Multiple Myeloma, NHL, Hodgkin's Lymphoma
Interventions
CD+8 T cell depletion
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 5, 2026, 7:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

NCT00582816
View directory record Official record
Conditions
Leukemia, Solid Tumors
Interventions
Clinimacs Cell Separation System, conditioning chemotherapy, DLI
Device · Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
6 Months to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 2 Interventional

Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer

NCT00020176
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation for T and B Cell Depletion

NCT00579124
View directory record Official record
Conditions
Immunodeficiencies
Interventions
CliniMACs
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 22 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 5, 2026, 7:23 PM EDT
Recruiting Phase 2 Interventional

Haploidentical HCT for Severe Aplastic Anemia

NCT04558736
View directory record Official record
Conditions
Aplastic Anemia, Bone Marrow Failure Syndrome
Interventions
Anti-Thymocyte Globulin (Rabbit), Fludarabine, Cyclophosphamide, Mesna, G-CSF, Total Lymphoid Irradiation (TLI), CliniMACS, HPC, A Infusion, CD45RA-depleted DLI
Drug · Radiation · Device + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 5, 2026, 7:23 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

NCT04282174
View directory record Official record
Conditions
Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions
CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine
Device · Procedure · Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
Up to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

NCT00566696
View directory record Official record
Conditions
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Hodgkin Lymphoma, Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
Interventions
CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard, Mycophenolate mofetil, Rituxan™, Alemtuzumab, Cyclophosphamide, Anti-thymocyte globulin (Rabbit), G-CSF, Muromonab
Device · Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 5, 2026, 7:23 PM EDT
Active, not recruiting Phase 2 Interventional

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

NCT02600208
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
CliniMACs
Device
Lead sponsor
Julie-An M. Talano
Other
Eligibility
Up to 23 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 5, 2026, 7:23 PM EDT
Withdrawn Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

NCT00874315
View directory record Official record
Conditions
Neuroblastoma
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation
Other · Drug · Procedure
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 5, 2026, 7:23 PM EDT
Terminated Not applicable Interventional

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

NCT00038818
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Multiple Myeloma, Non Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
Interventions
CD8 Depleted Donor Lymphocyte
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

NCT00683046
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Lymphoid Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia, Myeloproliferative Disorder, Anemia, Aplastic, Myelodysplastic Syndromes
Interventions
Fludarabine, Melphalan, Stem cells, Campath
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 5, 2026, 7:23 PM EDT
Recruiting Not applicable Interventional

Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection

NCT01189786
View directory record Official record
Conditions
Stem Cell Transplant, Allogeneic
Interventions
CliniMACS CD34 Reagent system
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Results available

Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

NCT00629798
View directory record Official record
Conditions
Acute Myeloid Leukemia, Advanced Myelodysplastic Syndromes
Interventions
Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 5, 2026, 7:23 PM EDT
Active, not recruiting Phase 3 Interventional

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

NCT05457556
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Busulfan, Cyclophosphamide, Echocardiography Test, Fludarabine, Haploidentical Hematopoietic Cell Transplantation, Lapine T-Lymphocyte Immune Globulin, Lumbar Puncture, Matched Unrelated Donor Hematopoietic Cell Transplantation, Melphalan, Methotrexate, Multigated Acquisition Scan, Mycophenolate Mofetil, Myeloablative Conditioning, Quality-of-Life Assessment, Questionnaire Administration, Rituximab, T-Cell Depletion Therapy, Tacrolimus, Thiotepa, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 5, 2026, 7:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation

NCT01596257
View directory record Official record
Conditions
Leukemia
Interventions
allogeneic hematopoietic stem cell transplantation, CliniMACS
Procedure · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 5, 2026, 7:23 PM EDT
Completed No phase listed Observational

Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

NCT01904175
View directory record Official record
Conditions
Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Oct 5, 2026, 7:23 PM EDT
Terminated Phase 2 Interventional Results available

T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation

NCT02350777
View directory record Official record
Conditions
Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function
Interventions
Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion, CliniMACS Cell Selection System
Procedure · Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 5, 2026, 7:23 PM EDT
Terminated Not applicable Interventional Results available

Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor

NCT01598025
View directory record Official record
Conditions
Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Non-Hodgkins Lymphoma
Interventions
total-body irradiation (TBI), thiotepa, fludarabine phosphate, melphalan, anti-thymocyte globulin, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, laboratory biomarker analysis
Radiation · Drug · Biological + 2 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 19 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 5, 2026, 7:23 PM EDT